Search

Search Constraints

You searched for: Author/Creator Bimbatti, Davide

Search Results

1. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Issue 1 (February 2023)

2. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. (September 2017)

3. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Issue 1 (2nd January 2022)

4. Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients. Issue 6 (31st March 2019)

5. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Issue 4 (April 2015)

6. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. Issue 4 (April 2015)

7. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. Issue 2 (March 2021)

8. De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. (November 2018)

9. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study. (20th March 2022)

10. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. Issue 2 (27th August 2020)